March 6, 2018 / 1:26 PM / 4 months ago

BRIEF-Citius Reports Progress In Hemorroid Treatment Program

March 6 (Reuters) - Citius Pharmaceuticals Inc:

* CITIUS REPORTS PROGRESS IN HEMORROID TREATMENT PROGRAM

* CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS

* CITIUS PHARMACEUTICALS INC - NEW FORMULATION, CITI-002, WILL COMBINE LIDOCAINE WITH HIGHER POTENCY CORTICOSTEROID

* CITIUS PHARMACEUTICALS INC - HELD A TYPE C MEETING WITH FDA TO DISCUSS RESULTS OF PHASE 2A STUDY

* CITIUS PHARMACEUTICALS - MEETING WITH FDA ALSO TO OBTAIN ITS VIEW ON PLANS TO SUPPORT POTENTIAL FORMULATION CHANGE FOR PLANNED PHASE 2B STUDY

* CITIUS PHARMACEUTICALS INC - REQUESTED FDA'S FEEDBACK ON PHASE 2B STUDY DESIGN

* CITIUS PHARMACEUTICALS - PRE-CLINICAL, CLINICAL DEVELOPMENT PROGRAMS FOR CITI-002 PLANNED TO BE SIMILAR TO THOSE OF CITI-001 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below